ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1270

Comparison of Clinical and Serological Features of Juvenile and Adult-Onset Neuropsychiatric Lupus in Spanish Patients

Sandra Garrote-Corral1, Alina Boteanu2, Walter A. Sifuentes-Giraldo1, Antía García-Fernández1, María Luz Gámir-Gámir1 and Antonio Zea Mendoza1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Neurologic involvement, Pediatric rheumatology and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Neuropsychiatric (NP) manifestations are a main cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (jSLE). Some studies suggest that they are more frequent and severe in jSLE than in adult-onset SLE (aSLE). We performed a study to compare the clinical and serological profile of pediatric and adult patients with neuropsychiatric lupus (NPSLE) treated in a Spanish tertiary center.

Methods: A retrospective study of patients with jSLE (age of onset: 0-18y) and aSLE (age of onset: >18y) seen in our center during the period 1988-2016 was performed. Case definitions of the American College of Rheumatology were used to identify NPSLE manifestations. Demographics, clinical and serological data were obtained through a review of their medical records.

Results: A total of 69 patients with NPSLE were included, aSLE 41 (59%) and jSLE 28 (41%), the comparison of groups is presented in the table. Most of them were Caucasian (92%), mean age at diagnosis in adults was 36.4 years (range: 19-68) and 13.9 years (range: 8-18) in children. The proportion of males was higher in the latter group. The mean duration of the disease was significantly greater in adults, as well as the time from SLE diagnosis to NP manifestation onset, although without significant difference. Central NP manifestations were the most frequent in both groups (aSLE 93%, jSLE 96%) regarding to the peripheral manifestations (aSLE 12%, jSLE 11%). The most frequent manifestations in aSLE were headache (29%), cerebrovascular disease (27%), seizures (17%) and myelopathy (15%), whereas in jSLE were seizures (46%), headache (29%), mood disorder/depression (25%), psychosis (18%) and autonomic disorders (18%). A significant group of patients presented ≥ 2 central manifestation during their evolution (aSLE 32%, jSLE 41%), with the mean number of manifestations in adults being 1.36 (range: 1-3) and in children 1.44 Range: 1-4 ). Patients with jSLE developed lupus nephritis (LN) with a significantly higher frequency, as well as higher titres of anti-DNA antibodies, erythrocyte sedimentation rate (ESR) and hypocomplementemia. During the study period there was mortality in 2 cases of aSLE and 2 jSLE (5% and 7%, respectively).

Juvenile NPSLE

Adult NPSLE

p-value

Nº of patients

28 (41%)

41 (59%)

–

Women:men

20:8

39:2

0.0060*

Time of disease (months)

19.8

232.5

0.0001*

NP manifestations at onset

7 (25%)

11 (27%)

0.8651

Time from diagnosis to NP manifestation (months)

42.4

87.1

0.1268

Lupus nephritis

16 (57%)

9 (22%)

0.0028*

Antiphospholipid syndrome

5 (18%)

10 (24%)

0.5182

ANA ≥ 1/1280

8 (29%)

11 (27%)

0.8736

Anti-DNA ab (IU/ml)

178.9

39.4

0.0005*

Anti-Ro/SSA ab

10 (36%)

17 (41%)

0.6308

Anticardiolipin ab

4 (14%)

10 (24%)

0.3054

Anti-ß2 glycopotein I ab

5 (18%)

7 (17%)

0.9328

Lupus anticoagulant

8 (29%)

10 (24%)

0.6977

Cryoglobulins

6 (21%)

3 (7%)

0.0874

ESR (mm/h)

53.8

35.7

0.0199*

CRP mg/l

4.6

4.7

0.9687

C3 low (< 80 mg/dl)

22 (79%)

16 (39%)

0.0012*

C4 low (< 16 mg/dl)

22 (79%)

13 (32%)

0.0001*

Conclusion: Our results corroborate that juvenile patients with NPSLE present higher disease activity compared to adults. There was no significant diference in the time from SLE diagnosis to NP manifestation onset, but tended to be shorter in jSLE. The spectrum of NPSLE was varied both groups and an important proportion developed ≥ 2 manifestation. Mortality continues to be important in NPSLE in both age groups.


Disclosure: S. Garrote-Corral, None; A. Boteanu, None; W. A. Sifuentes-Giraldo, None; A. García-Fernández, None; M. L. Gámir-Gámir, None; A. Zea Mendoza, None.

To cite this abstract in AMA style:

Garrote-Corral S, Boteanu A, Sifuentes-Giraldo WA, García-Fernández A, Gámir-Gámir ML, Zea Mendoza A. Comparison of Clinical and Serological Features of Juvenile and Adult-Onset Neuropsychiatric Lupus in Spanish Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparison-of-clinical-and-serological-features-of-juvenile-and-adult-onset-neuropsychiatric-lupus-in-spanish-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-and-serological-features-of-juvenile-and-adult-onset-neuropsychiatric-lupus-in-spanish-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology